Log In
Print
BCIQ
Print
Print this Print this
 

PPI-668

  Manage Alerts
Collapse Summary General Information
Company Presidio Pharmaceuticals Inc.
DescriptionSecond-generation HCV NS5A protein inhibitor
Molecular Target HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection in treatment-naïve patients; Treat HCV genotype 1 infection
Regulatory Designation

Partner

Ascletis Pharmaceuticals Co. Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$100.7M

$100.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today